Literature DB >> 19777583

Integrated solution to purification challenges in the manufacture of a soluble recombinant protein in E. coli.

Maire H Caparon1, Kevin J Rust, Alan K Hunter, Joseph K McLaughlin, Kristen E Thomas, John T Herberg, Robert E Shell, Paul B Lanter, Bruce F Bishop, Robert L Dufield, Xing Wang, Sa V Ho.   

Abstract

Apolipoprotein A 1 Milano (ApoA-1M), the protein component of a high-density lipoprotein (HDL) mimic with promising potential for reduction of atherosclerotic plaque, is produced at large scale by expression in E. coli. Significant difficulty with clearance of host cell proteins (HCPs) was experienced in the original manufacturing process despite a lengthy downstream purification train. Analysis of purified protein solutions and intermediate process samples led to identification of several major HCPs co-purifying with the product and a bacterial protease potentially causing a specific truncation of ApoA-1M found in the final product. Deletion of these genes from the original host strain succeeded in substantially reducing the levels of HCPs and the truncated species without adversely affecting the overall fermentation productivity, contributing to a much more efficient and robust new manufacturing process. 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19777583     DOI: 10.1002/bit.22542

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  12 in total

1.  A facile method for isolation of recombinant human apolipoprotein A-I from E. coli.

Authors:  Nikita Ikon; Jennifer Shearer; Jianfang Liu; Jesse J Tran; ShiBo Feng; Ayako Kamei; Jennifer A Beckstead; Robert S Kiss; Paul M Weers; Gang Ren; Robert O Ryan
Journal:  Protein Expr Purif       Date:  2017-03-20       Impact factor: 1.650

2.  Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.

Authors:  Herman J Kempen; Monica Gomaraschi; S Eralp Bellibas; Stephanie Plassmann; Brad Zerler; Heidi L Collins; Steven J Adelman; Laura Calabresi; Peter L J Wijngaard
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

Review 3.  Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.

Authors:  Chung-Jr Huang; Henry Lin; Xiaoming Yang
Journal:  J Ind Microbiol Biotechnol       Date:  2012-01-18       Impact factor: 3.346

Review 4.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

5.  Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins.

Authors:  Uwe Mamat; Kathleen Wilke; David Bramhill; Andra Beate Schromm; Buko Lindner; Thomas Andreas Kohl; José Luis Corchero; Antonio Villaverde; Lana Schaffer; Steven Robert Head; Chad Souvignier; Timothy Charles Meredith; Ronald Wesley Woodard
Journal:  Microb Cell Fact       Date:  2015-04-16       Impact factor: 5.328

6.  Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size.

Authors:  Herman J Kempen; Dorota B Schranz; Bela F Asztalos; James Otvos; Elias Jeyarajah; Denise Drazul-Schrader; Heidi L Collins; Steven J Adelman; Peter L J Wijngaard
Journal:  J Lipids       Date:  2014-11-12

7.  A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease.

Authors:  D G Kallend; J A A Reijers; S E Bellibas; A Bobillier; H Kempen; J Burggraaf; M Moerland; P L J Wijngaard
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2015-12-11

8.  MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216.

Authors:  Joannes A A Reijers; D G Kallend; K E Malone; J W Jukema; P L J Wijngaard; J Burggraaf; M Moerland
Journal:  Cardiovasc Drugs Ther       Date:  2017-08       Impact factor: 3.727

Review 9.  Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals.

Authors:  Joannes A A Reijers; Karen E Malone; Jeffrey J Bajramovic; Richard Verbeek; Jacobus Burggraaf; Matthijs Moerland
Journal:  Br J Clin Pharmacol       Date:  2019-05-29       Impact factor: 4.335

10.  Reconstituted HDL (Milano) Treatment Efficaciously Reverses Heart Failure with Preserved Ejection Fraction in Mice.

Authors:  Mudit Mishra; Ilayaraja Muthuramu; Joseph Pierre Aboumsallem; Herman Kempen; Bart De Geest
Journal:  Int J Mol Sci       Date:  2018-10-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.